Recent News

• 04.23.2025 - PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
• 03.07.2025 - PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
• 02.05.2025 - PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Recent Filings

• 03.27.2025 - EX-99.1 EX-99.1
• 03.27.2025 - 8-K Current report
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.13.2025 - EX-99.1 EX-99.1
• 03.13.2025 - 8-K Current report
• 03.07.2025 - EX-99.1 EX-99.1
• 03.07.2025 - 8-K Current report
• 03.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - 424B5 Prospectus [Rule 424(b)(5)]